New pill shows promise in shrinking spleens for myelofibrosis patients

NCT ID NCT05020652

Completed Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called TQ05105 in 107 people with moderate to high-risk myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen. The goal was to see if TQ05105 could shrink the spleen better than the standard drug hydroxyurea. Participants took either TQ05105 or hydroxyurea for 24 weeks, and doctors measured spleen size using scans. The trial is complete, and results will show if TQ05105 is a more effective treatment option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE AND HIGH RISK MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE AND HIGH RISK MYELOFIBROSIS

Contacts and locations

Locations

Guangdong Provincial Peoples Hospital

Guangzhou, Guangdong, 510055, China
Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College

Tianjin, Tianjin Municipality, 300020, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100005, China
West China School of Medicine / West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.